Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Institute of Hematology & Blood Diseases Hospital, China
University of Utah
University of Utah
Thomas Jefferson University
University of Washington
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Shanghai Changzheng Hospital
Peking University People's Hospital
Mayo Clinic
Masonic Cancer Center, University of Minnesota
The First Affiliated Hospital of Soochow University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Pfizer
Array BioPharma
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Fred Hutchinson Cancer Center
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
University of Michigan Rogel Cancer Center
Senesco Technologies, Inc.
IRCCS Centro di Riferimento Oncologico della Basilicata
Clinical Service, China